Collateral for a security interest recorded Apr 8, 2021 (RTW Investments Icav).
Term ends Jan 20, 2031 · High confidence
20-year base term ends Jan 20, 2031
Held by Urogen Pharma Ltd.
Filed Dec 1, 2016 as application 15/366,256 · Granted Apr 24, 2018
Base term, 20 years from filing
Today
2011
2031
Clock starts
Jan 20, 2011
Jan 20, 2011
Term ends
Jan 20, 2031
Jan 20, 2031
Granted
Apr 24, 2018
Apr 24, 2018
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,039,832, US 9,040,074, to Jan 20, 2031. The term already ends on or before that date, so the cap shortened nothing.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
13
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 20, 2011, when application PCT/IL2011/000069, the earliest non-provisional in its chain, was filed (this one was filed Dec 1, 2016) | Jan 20, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,039,832, US 9,040,074) | resolves to Jan 20, 2031, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 20, 2031 | High confidence |
This family
| US 9,040,074 | In force Jan 2031 | Jan 2031 |
| US 10,471,150 | In force Jan 2031 | Jan 2031 |
| US 10,039,832 | In force Jan 2031 | Jan 2031 |
| US 9,950,069 | this patent Jan 2031 | Jan 2031 |
| Application 16/518,511 | Abandoned not computed | not computed |
| Application 17/566,882 | Abandoned not computed | not computed |
| Application 18/129,497 | Abandoned not computed | not computed |
| Application 18/129,543 | Abandoned not computed | not computed |
8 of 13 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 8, 2018 Reel 44556, frame 637 | Holzer, Asher; Daniel, Dorit; Mullerad, Michael; De La Zerda, Jaime; Shpolansky, Uri; Malchi, Nadav; Dollberg, Yosh; Tal, Dor; Yavin, Yossi; Konorty, Marina | Theracoat Ltd. | Assignment of Assignor's Interest |
| Jan 8, 2018 Reel 45016, frame 287 | Theracoat Ltd. | Urogen Pharma Ltd. | Change of Name |
| Apr 8, 2021 Reel 55868, frame 385 | Urogen Pharma Ltd. | RTW Investments Icav | Security Interest |
| Mar 18, 2022 Reel 59302, frame 501 | Urogen Pharma Ltd. | Biopharma Credit PLC | Security Interest |
| May 19, 2022 Reel 60121, frame 591 | Urogen Pharma Ltd. | RTW Investments Ica V | Amended and Restated Patent Security Agreement |
| Mar 18, 2024 Reel 66805, frame 346 | Urogen Pharma Ltd. | Biopharma Credit PLC | Patent Security Agreement |
| Mar 6, 2025 Reel 70434, frame 319 | Urogen Pharma Ltd. | Biopharma Credit PLC [Collateral Agent] | Amended and Restated Patent Security Agreement |
| Aug 18, 2025 Reel 72472, frame 233 | Urogen Pharma Ltd. | Biopharma Credit PLC, as Collateral Agent | Amended and Restated Patent Security Agreement |
| Mar 2, 2026 Reel 74994, frame 338 | Urogen Pharma Ltd. | Biopharma Credit PLC, as Collateral Agent | Second Amended and Restated Patent Security Agreement |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Jan 2031
Term ends Jan 20, 2031. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,039,832, US 9,040,074, ends no earlier than this term, so it caps nothing.
Citations
15
later US patents cite this one
That is top 25% of utility patents granted in 2018 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.